| Jun 27 |
Aethlon Medical GAAP EPS of -$4.86 beats by $0.33
|
| Jun 27 |
Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
|
| Jun 26 |
Aethlon Medical FY 2024 Earnings Preview
|
| Jun 24 |
AEMD: Ethics Committee Approval for Safety, Feasibility, Dose-Finding Trial Important Step in Advancing the Hemopurifier
|
| Jun 21 |
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
|
| Jun 20 |
What's Next in Treatments for Cancer Patients with Solid Tumors?
|
| Jun 18 |
Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial
|
| Jun 17 |
(AEMD) - Analyzing Aethlon Medical's Short Interest
|
| Jun 7 |
The Hunt for Virus Treatments Continues Post Covid-19
|
| Jun 6 |
Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
|
